ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02155803
Previous Study | Return to List | Next Study

ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02155803
Recruitment Status : Unknown
Verified January 2015 by Marc A. Judson, MD, Albany Medical College.
Recruitment status was:  Not yet recruiting
First Posted : June 4, 2014
Last Update Posted : January 26, 2015
Sponsor:
Information provided by (Responsible Party):
Marc A. Judson, MD, Albany Medical College

Brief Summary:
ACTHAR Gel has activity in sarcoidosis associated hypercalciuria and calcium dysregulation.

Condition or disease Intervention/treatment Phase
Sarcoidosis Hypercalcemia Due to Sarcoidosis Drug: ACTHAR Gel (adrenocorticotropic hormone) Phase 2 Phase 3

Detailed Description:

Sarcoidosis is a multisystem granulomatous disease of unknown cause. Although sarcoidosis most commonly affects the lung, it may affect any organ. Although corticosteroids are recognized as the drug of choice for sarcoidosis. ACTH(adrenocorticotropic hormone) is the only drug that is FDA-approved for this disorder. However, there is limited data on the efficacy of ACTH for this condition.

Calcium metabolism is disregulated in active sarcoidosis. The primary abnormality in calcium metabolism stems from an increased 1-α hydroxylase activity in sarcoid alveolar macrophages that converts 25-hydroxyvitamin D to 1, 25-dihydroxyvitamin D, the active form of the vitamin. This can result in hypercalcemia, hypercalciuria, nephrocalcinosis, nephrolithiasis, interstitial nephritis, glomerulonephritis, acute and chronic kidney disease. Importantly, almost of the renal manifestations stem from disordered calcium metabolism. Unlike other organ manifestations of sarcoidosis, the disorder of calcium metabolism is more common in whites compared to african americans.Compared to hypercalcemia, hypercalciuria is three times more common in sarcoidosis, nevertheless, it has largely been ignored.

In general, the patient with hypercalcemia should be advised to avoid sunlight, curtail intake of major sources of dietary calcium and vitamin D, and drink ample fluids.If the patient is symptomatic, serum calcium is greater than 11 mg/dl, the serum creatinine is elevated, or the patient has nephrolithiasis, drug therapy is usually required. The drug of choice is prednisone at an initial daily dose of 20 - 40 mg/day.Unfortunately, prolonged corticosteroid therapy may result in unacceptable side effects including osteoporosis. This is particularly important as elevated calcitriol observed in patients with sarcoidosis can further jeopardize bone structure by resorption. Alternative medications that have shown benefit for sarcoidosis associated calcium dysregulation have included chloroquine,hydroxychloroquine, ketoconazole.

Not only may ACTHER GEL have obvious anti-inflammatory effects by resulting in corticosteroid production, but it may also activate melanocortin receptors. The melanocortin system has powerful anti-inflammatory properties that may be beneficial in the treatment of sarcoidosis.

We believe that there are several specific advantages of assessing the effectiveness of anti-sarcoidosis therapy by examining sarcoidosis-associated disorders of calcium metabolism.

  1. The measures of granulomatous activity (serum calcium, urinary calcium, serum 25-hydroxyvitamin D, and serum 1, 25-dihydroxyvitamin D levels) are directly related to the granulomatous inflammation of sarcoidosis.
  2. These parameters can be accurately and objectively quantified. This is an important issue in sarcoidosis as the endpoint for involvement of the lungs, skin, and eyes is problematic because it is either inexact and/or not unidimensional.
  3. These constituents can be easily used to clinically monitor sarcoidosis. This is not the case for other forms of sarcoidosis including involvement of the lung and skin.

    • Although hypercalciuria and disordered calcium metabolism is not as common a manifestation of sarcoidosis as lung involvement, there is little evidence that the anti-granulomatous response to this disease is organ specific. In a randomized double-blind placebo control trial of infliximab for pulmonary sarcoidosis, extrapulmonary sarcoidosis also responded to this therapy.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study
Study Start Date : February 2015
Estimated Primary Completion Date : June 2015
Estimated Study Completion Date : November 2015


Arm Intervention/treatment
Experimental: Sarcoidosis related Calcium Dysregulation
Subjects with Sarcoidosis associated calcium dysregulation will be administered 80 units of Acthar Gel (adrenocorticotropic hormone) twice a week for 12 weeks. Clinical visits will be scheduled for -30 days, day of 1st dose and 4,8,12 and 16 week after 1st dose to monitor the health of subjects.
Drug: ACTHAR Gel (adrenocorticotropic hormone)
ACTHAR GEL (adrenocorticotropic hormone) 80 units subcutaneously twice weekly for 12 weeks




Primary Outcome Measures :
  1. Reduction of 24 hour urine calcium [ Time Frame: Between week 0 and week 12. ]
    Reduction of 24 hour urine calcium in patients with sarcoidosis associated hypercalciuria (primary endpoint) between week 0 and week 12.


Secondary Outcome Measures :
  1. Change in serum calcium during 12 week ACTHAR GEL treatment [ Time Frame: Baseline compared to 12 weeks. ]
  2. Change in 1,25 di-hydroxy Vitamin D during 12 week ACTHAR GEL treatment [ Time Frame: Baseline compared to 12 weeks. ]
  3. Change in patient global VAS during 12 week ACTHAR GEL treatment [ Time Frame: Baseline to 12 weeks ]
  4. Change in physician global VAS during 12 week ACTHAR GEL treatment [ Time Frame: Baseline to 12 Weeks ]
  5. Change in urinary symptoms during 12 week ACTHAR GEL treatment [ Time Frame: Baseline to 12 Weeks ]
  6. Change in Short Form-36 during 12 week ACTHAR GEL treatment [ Time Frame: Baseline to 12 Weeks ]
  7. Change in Sarcoidosis Health Questionnaire during 12 week ACTHAR GEL treatment [ Time Frame: Baseline to 12 Weeks ]
  8. Change in eCOST during 12 week ACTHAR gel treatment [ Time Frame: Baseline to 12 Weeks ]
  9. Change in adjusted eCOST (eCOSTadj) calculated as the eCOST/# organs with an eCOST score > 022 during 12 week ACTHAR gel treatment [ Time Frame: Baseline to 12 Weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age greater than 18 years old.
  2. Able to understand English to the point of comprehending the informed consent form.
  3. Biopsy proven sarcoidosis.
  4. Documented hypercalciuria (urinary excretion of > 4mg/kg of calcium/day) or hypercalcemia within 4 weeks of study entry.
  5. Historical evidence that the patient's hypercalciuria/hypercalcemia is related to sarcoidosis. This should include a serum parathyroid hormone (PTH) level which is not elevated.

Exclusion Criteria:

  1. A change in anti-sarcoidosis medications within 3 months of study entry.
  2. A history of hyperparathyroidism or another non-sarcoidosis cause of hypercalcemia/hypercalciuria
  3. A history of Cushing's disease.
  4. Have a diagnosis of a medical disorder other than sarcoidosis that in the opinion of the investigator would complicate the evaluation of response treatment.
  5. Have used any investigational drug within 1 month prior to screening or within 5 half-lives of the investigational agent, whichever is longer.
  6. Use of loop or thiazide diuretics for hypertension or other disorders.
  7. Chronic use of antacids.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02155803


Contacts
Contact: Haroon Chaudhry, MBBS 518-262-1542 chaudhh@mail.amc.edu
Contact: Marc A. Judson, MD 518-262-5196 judsonm@mail.amc.edu

Locations
United States, New York
Albany Medical College Not yet recruiting
Albany, New York, United States, 12208
Contact: Haroon Chaudhry, MBBS    518-262-1542    chaudhh@mail.amc.edu   
Principal Investigator: Marc A. Judson, MD         
Sponsors and Collaborators
Albany Medical College
Investigators
Principal Investigator: Marc A Judson, MD Albany Medical College

Responsible Party: Marc A. Judson, MD, Albany Medical College
ClinicalTrials.gov Identifier: NCT02155803     History of Changes
Other Study ID Numbers: AMCMAJCA2014
First Posted: June 4, 2014    Key Record Dates
Last Update Posted: January 26, 2015
Last Verified: January 2015

Keywords provided by Marc A. Judson, MD, Albany Medical College:
Sarcoidosis-Associated Calcium Dysregulation
Sarcoidosis-Associated hypercalciuria
hypercalcemia
hypercalciuria
nephrocalcinosis
nephrolithiasis
interstitial nephritis
glomerulonephritis
acute kidney disease
chronic kidney disease

Additional relevant MeSH terms:
Sarcoidosis
Hypercalcemia
Lymphoproliferative Disorders
Lymphatic Diseases
Calcium Metabolism Disorders
Metabolic Diseases
Water-Electrolyte Imbalance
Hormones
Adrenocorticotropic Hormone
Melanocyte-Stimulating Hormones
Calcium, Dietary
beta-Endorphin
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Bone Density Conservation Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action